Haemonetics Corporation (HAE)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $5.60B
Last updated: Nov 17, 2026 at 11:06 AM ET
Haemonetics Corporation (HAE) Earnings: Report Dates and Results
Haemonetics (HAE) is expected to report earnings on Feb 3, 2027. In the quarter ended Sep 30, 2026, Haemonetics reported EPS of $1.35, above the $1.30 estimate. It beat the EPS estimate in each of the last 20 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
HAE has an expected report date of Feb 3, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 3.1% below the $1.31 reported for the quarter ended Dec 31, 2025.
HAE Earnings Call
The latest HAE earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, HAE beat 36, missed 3 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $357.76M, up 9.3% from $327.31M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.35 | $1.30 | $1.21 - $1.37 | +3.85% | Beat | +6.3% | 11 | 1 up, 0 down | Nov 5, 2026 | $357.76M |
| Jun 30, 2026 | $1.14 | $1.07 | $1.02 - $1.14 | +6.54% | Beat | +3.6% | 11 | 1 up, 1 down | Aug 6, 2026 | $339.38M |
| Mar 31, 2026 | $1.29 | $1.27 | $1.25 - $1.31 | +1.57% | Beat | +4.0% | 11 | 2 up, 8 down | May 7, 2026 | $346.35M |
| Dec 31, 2025 | $1.31 | $1.25 | $1.18 - $1.28 | +4.80% | Beat | +10.1% | 11 | 3 up, 8 down | Feb 5, 2026 | $338.97M |
| Sep 30, 2025 | $1.27 | $1.11 | $1.07 - $1.16 | +14.41% | Beat | +13.4% | 11 | 1 up, 0 down | Nov 6, 2025 | $327.31M |
| Jun 30, 2025 | $1.10 | $1.01 | $0.95 - $1.10 | +8.91% | Beat | +7.8% | 10 | 0 up, 1 down | Aug 7, 2025 | $321.39M |
| Mar 31, 2025 | $1.24 | $1.22 | $1.17 - $1.28 | +1.64% | Beat | +37.8% | 10 | N/A | May 8, 2025 | $330.60M |
| Dec 31, 2024 | $1.19 | $1.17 | $1.12 - $1.21 | +1.71% | Beat | +14.4% | 10 | 0 up, 1 down | Feb 6, 2025 | $348.54M |
| Sep 30, 2024 | $1.12 | $1.07 | $1.03 - $1.10 | +4.67% | Beat | +13.1% | 10 | 0 up, 0 down | Nov 7, 2024 | $345.51M |
| Jun 30, 2024 | $1.02 | $1.01 | $0.95 - $1.07 | +0.99% | Beat | -2.9% | 7 | 0 up, 0 down | Aug 8, 2024 | $336.17M |
| Mar 31, 2024 | $0.90 | $0.89 | $0.88 - $0.92 | +1.12% | Beat | +16.9% | 7 | 0 up, 0 down | May 9, 2024 | $343.29M |
| Dec 31, 2023 | $1.04 | $0.94 | $0.91 - $1.00 | +10.64% | Beat | +22.4% | 7 | 0 up, 0 down | Feb 8, 2024 | $336.25M |
| Sep 30, 2023 | $0.99 | $0.89 | $0.83 - $0.97 | +11.24% | Beat | +19.3% | 7 | 0 up, 0 down | Nov 2, 2023 | $318.18M |
| Jun 30, 2023 | $1.05 | $0.73 | $0.67 - $0.84 | +43.84% | Beat | +81.0% | 8 | 0 up, 0 down | Aug 8, 2023 | $311.33M |
| Mar 31, 2023 | $0.77 | $0.70 | $0.63 - $0.74 | +10.00% | Beat | +18.5% | 8 | 0 up, 0 down | May 11, 2023 | $304.42M |
| Dec 31, 2022 | $0.85 | $0.82 | $0.72 - $0.89 | +3.66% | Beat | +1.2% | 8 | 1 up, 0 down | Feb 7, 2023 | $305.30M |
| Sep 30, 2022 | $0.83 | $0.67 | $0.63 - $0.72 | +23.88% | Beat | +38.3% | 8 | 1 up, 0 down | Nov 7, 2022 | $297.49M |
| Jun 30, 2022 | $0.58 | $0.51 | $0.43 - $0.58 | +13.73% | Beat | +16.0% | 7 | 1 up, 0 down | Aug 10, 2022 | $261.46M |
| Mar 31, 2022 | $0.65 | $0.60 | $0.56 - $0.62 | +8.33% | Beat | +41.3% | 7 | 0 up, 0 down | May 10, 2022 | $265.00M |
| Dec 31, 2021 | $0.84 | $0.73 | $0.67 - $0.80 | +15.07% | Beat | +3.7% | 8 | 2 up, 1 down | Feb 8, 2022 | $259.77M |
| Sep 30, 2021 | $0.60 | $0.61 | $0.49 - $0.67 | -1.64% | Miss | -3.2% | 8 | N/A | Nov 9, 2021 | $239.90M |
| Jun 30, 2021 | $0.50 | $0.45 | $0.31 - $0.57 | +11.11% | Beat | +8.7% | 7 | N/A | Aug 11, 2021 | $228.53M |
| Mar 31, 2021 | $0.46 | $0.67 | $0.60 - $0.71 | -31.34% | Miss | -33.3% | 7 | N/A | May 13, 2021 | $225.03M |
| Dec 31, 2020 | $0.81 | $0.65 | $0.56 - $0.71 | +24.62% | Beat | -13.8% | 7 | N/A | Feb 2, 2021 | $240.37M |
| Sep 30, 2020 | $0.62 | $0.51 | $0.45 - $0.59 | +21.57% | Beat | -28.7% | 7 | N/A | Nov 4, 2020 | $209.49M |
| Jun 30, 2020 | $0.46 | $0.41 | $0.32 - $0.55 | +12.20% | Beat | -43.2% | 7 | N/A | Aug 4, 2020 | $195.58M |
| Mar 31, 2020 | $0.69 | $0.73 | $0.67 - $0.77 | -5.48% | Miss | +13.1% | 7 | N/A | May 5, 2020 | $238.49M |
| Dec 31, 2019 | $0.94 | $0.76 | $0.73 - $0.82 | +23.68% | Beat | +49.2% | 7 | N/A | Feb 4, 2020 | $258.97M |
| Sep 30, 2019 | $0.87 | $0.72 | $0.56 - $0.74 | +20.83% | Beat | +55.4% | 7 | N/A | Nov 1, 2019 | $252.57M |
| Jun 30, 2019 | $0.81 | $0.64 | $0.60 - $0.67 | +26.56% | Beat | +37.3% | 7 | N/A | Aug 6, 2019 | $238.45M |
| Mar 31, 2019 | $0.61 | $0.55 | $0.52 - $0.57 | +10.91% | Beat | +41.9% | 7 | N/A | May 7, 2019 | $249.29M |
| Dec 31, 2018 | $0.63 | $0.59 | $0.57 - $0.61 | +6.78% | Beat | +1.6% | 7 | N/A | Feb 5, 2019 | $247.36M |
| Sep 30, 2018 | $0.56 | $0.54 | $0.50 - $0.57 | +3.70% | Beat | +16.7% | 7 | N/A | Nov 6, 2018 | $241.58M |
| Jun 30, 2018 | $0.59 | $0.42 | $0.37 - $0.47 | +40.48% | Beat | +78.8% | 8 | N/A | Aug 7, 2018 | $229.35M |
| Mar 31, 2018 | $0.43 | $0.43 | $0.40 - $0.46 | 0.00% | In line | +10.3% | 8 | N/A | May 8, 2018 | $233.55M |
| Dec 31, 2017 | $0.62 | $0.44 | $0.41 - $0.46 | +40.91% | Beat | +44.2% | 8 | N/A | Feb 6, 2018 | $234.04M |
| Sep 30, 2017 | $0.48 | $0.41 | $0.38 - $0.46 | +17.07% | Beat | +4.3% | 8 | N/A | Nov 7, 2017 | $225.38M |
| Jun 30, 2017 | $0.33 | $0.30 | $0.25 - $0.37 | +10.00% | Beat | +32.0% | 8 | N/A | Aug 7, 2017 | $210.95M |
| Mar 31, 2017 | $0.39 | $0.38 | N/A | +2.63% | Beat | +5.4% | N/A | N/A | May 8, 2017 | $228.07M |
| Dec 31, 2016 | $0.43 | $0.40 | N/A | +7.50% | Beat | -10.4% | N/A | N/A | Feb 6, 2017 | $227.84M |
Annual EPS
EPS for the fiscal year ended Mar 31, 2026 was $4.97, up 8.8% from the year before. It was $1.53 for the year ended Mar 31, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Mar 31, 2026 | $4.97 | +8.8% |
| Mar 31, 2025 | $4.57 | +14.8% |
| Mar 31, 2024 | $3.98 | +31.4% |
| Mar 31, 2023 | $3.03 | +17.0% |
| Mar 31, 2022 | $2.59 | +10.2% |
| Mar 31, 2021 | $2.35 | -29.0% |
| Mar 31, 2020 | $3.31 | +38.5% |
| Mar 31, 2019 | $2.39 | +28.5% |
| Mar 31, 2018 | $1.86 | +21.6% |
| Mar 31, 2017 | $1.53 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,200 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,193 | 12 | |
| 2026Q2 | Jun 30, 2026 | 6,327 | 10 | |
| 2026Q1 | Mar 31, 2026 | 8,429 | 14 | |
| 2025Q4 | Dec 31, 2025 | 9,275 | 12 | |
| 2025Q3 | Sep 30, 2025 | 10,878 | 13 | |
| 2025Q2 | Jun 30, 2025 | 8,391 | 12 | |
| 2025Q1 | Mar 31, 2025 | 5,924 | 10 | |
| 2024Q4 | Dec 31, 2024 | 9,046 | 11 |
2026Q3 Earnings Call
Opening remarks
Olga Guyette Vice President, Investor Relations and Treasury Good morning, and thank you for joining us for Haemonetics Third Quarter Fiscal Year 2026 Conference Call and Webcast. I'm joined today by Christopher Simon, our CEO, and James D'Arecca, our CFO. This morning, we released our third quarter and year-to-date fiscal 2026 results and updated full-year fiscal 2026 guidance. The materials, including our earnings release, Form 10-Q, and the supplemental earnings presentation, are available on our Investor Relations website and in this morning's press release. Before we begin, I'd like to remind everyone that we will use both reported and organic revenue growth rates that exclude the impact of FX, the divestiture of the whole blood product line, and the exit of certain liquid solution products. Organic Growth ex CSL also excludes the impact of the previously disclosed transition of CSL's US disposable business. We'll also refer to other non-GAAP financial measures to help investors understand Haemonetics' ongoing business performance. Please note that these measures exclude certain charges and income items. A full list of excluded items, reconciliations to our GAAP results, and comparisons with the prior year periods are provided in our earnings release. Our remarks today include forward-looking statements, and our actual results may differ materially from the anticipated results. Factors that may cause our results to differ include those referenced in the safe harbor statement in today's release, and in our other SEC filings. We do not undertake any obligation to update these forward-looking statements. And now I'd like to turn it over to Christopher Simon.
Christopher Simon Chief Executive Officer (CEO) Thanks, Olga. Good morning, and thank you for joining us today. We delivered a strong quarter and we are raising our full-year revenue, earnings, and free cash flow guidance. Nexus and TEG delivered outsized growth driven by sustained share gains, innovation-based pricing, and durable end-market demand, demonstrating the strength and resilience of these core products and our increasingly productive operating model. Third-quarter revenue was $339 million, bringing year-to-date revenue to $988 million. Reported revenue reflects the $153 million impact of last year's portfolio transitions. Allowing for these nonrecurring items, underlying performance remains strong, with organic growth ex CSL of 8% in the quarter and 10% year-to-date. Adjusted earnings per share increased 10% in the quarter and 11% year-to-date to $1.31 and $3.67 per share, respectively, underscoring both the quality and the durability of our earnings. With that context, let's review our businesses in more detail. Hospital revenue was $144 million in the quarter and $429 million year-to-date, down 1% in the quarter and up 2% year-to-date organically, as strong performance in Blood Management Technologies offset softness in Interventional Technologies.
Frequently Asked Questions About HAE
When is Haemonetics's next earnings date?
Haemonetics's next earnings report is expected for Feb 3, 2027.
Did HAE beat earnings estimates last quarter?
Yes. Haemonetics reported EPS of $1.35 for the quarter ended Sep 30, 2026, above the $1.30 estimate, a 3.85% surprise.
What EPS do analysts expect from HAE next quarter?
The consensus EPS estimate for Haemonetics for the quarter ending Dec 31, 2026 is $1.27 from 12 analysts, with estimates from $1.16 to $1.43.
How often does HAE beat earnings estimates?
Haemonetics beat the EPS estimate in each of the last 20 quarters, with an average surprise of +9.53%.
HAE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts